Moderna and Merck announced Wednesday that their personalized mRNA neoantigen therapy, intismeran autogene, combined with Keytruda, met the primary endpoint of recurrence-free survival (RFS) and the key secondary endpoint of distant metastasis-free survival (DMFS) in a Phase III trial for resected high-risk melanoma. This marks the first positive Phase III readout for a personalized neoantigen therapy and for mRNA cancer treatments overall. Moderna shares skyrocketed 176.97% that day to close at $174.38, adding roughly $44 billion in market value; Thursday saw a 23.55% pullback to $133.31, with trading volume around 97.36 million shares. The scientific breakthrough was confirmed, but the market quickly began repricing for the fact that the magnitude of benefit remains unknown.

What the trial did, and what the company didn't say

INTerpath-001 enrolled 1,137 patients with completely resected, treatment-naive Stage IIB-IV cutaneous melanoma, randomized 2:1 in a double-blind, placebo-controlled design. The combination arm received intismeran 1 mg via intramuscular injection every three weeks for up to nine doses, alongside Keytruda 400 mg every six weeks for up to nine cycles, totaling approximately 56 weeks of treatment; the control arm received Keytruda alone. A pre-specified interim analysis showed the combination achieved "statistically significant and clinically meaningful" improvements in both RFS and DMFS; overall survival (OS) data are not yet mature, and the trial continues follow-up. The safety profile was consistent with prior studies, with no new signals. Ocular/mucosal melanoma and unresectable metastatic disease were excluded.

Intismeran is customized based on each patient's tumor mutation "fingerprint," encoding up to approximately 34 neoantigens delivered via lipid nanoparticles to train the immune system to recognize residual cancer cells after surgery. It is not a preventive vaccine but an adjuvant postsurgical therapy aimed at reducing recurrence and distant metastasis. Merck's Vice President of Oncology Clinical Research, Shweta Jain, noted that despite advances in adjuvant therapy, many patients still face recurrence risk after surgery; trial leader Georgina Long of the Melanoma Institute Australia called it a "milestone" in adjuvant melanoma treatment. Moderna CEO Stéphane Bancel said that designing mRNA treatments for an individual patient's cancer "was just a vision for many years, and we're turning it into a reality."

The critical gap is equally striking: the press release did not disclose hazard ratios, confidence intervals, p-values, or absolute benefit. The Phase II KEYNOTE-942 five-year follow-up presented at ASCO 2026 showed the combination reduced recurrence or death risk by 49% (HR=0.51) and distant metastasis or death risk by 59% (HR=0.411). Whether the Phase III replicates this magnitude will be revealed at an upcoming international medical conference. The two companies will use these results to engage with the FDA and other regulators for filing, with profits split evenly as agreed. The INTerpath program also covers approximately nine Phase II/III trials in non-small cell lung cancer, bladder cancer, renal cell carcinoma, and others, with melanoma serving as the first report card on whether the platform can be extrapolated.

Stock: A century-scale single-day surge, then the short squeeze unwound the next day

Closing Tuesday at $62.96, the stock hit an intraday high of $176.66 Wednesday before closing at $174.38, with volume of approximately 187-188 million shares, dozens of times the usual level. Merck rose about 12% over the same period. mRNA peers like BioNTech also rallied. Seeking Alpha called it one of the largest single-day gains for an S&P 500 component this century. Thursday opened higher but sold off steadily, closing at $133.31, down 23.55%, with an intraday low of $128.61; market value fell from roughly $69.6 billion back to about $53.2 billion.

Sell-side analysts attributed the surge to three components: scientific repricing, short covering, and crowded fast money. Brookline's Leah Cann described the heavy short interest as "poured with paraffin wax"; UBS's Michael Yee noted that single-day volume approached half of the float, and once covering and short-term repositioning were exhausted, the pullback was inevitable. UBS raised its price target from $50 to $150, maintaining Neutral. RBC's Luca Issi lifted the target from $45 to $130, keeping Sector Perform, stating the scientific breakthrough is valid but the risk-reward is more balanced after the surge. Piper Sandler maintained Overweight with a target raised to $167.

Wall Street is buying the platform, but also waiting for the hazard ratio

The most comprehensive model comes from Bank of America. Analyst Alec Stranahan upgraded the rating from Underperform to Neutral, raising the price target from $40 to $170, calling this a "watershed moment" for Moderna: the company can now move beyond dependence on infectious diseases and potentially ease the capital expenditure overhang. He raised his unadjusted global peak sales assumption for intismeran to $54 billion, increased the probability of success in adjuvant melanoma to 85% with a 60% peak share, and simultaneously raised assumptions for renal cell carcinoma and lung cancer indications, with a price per dose assumption of $260,000 to align with recent oncology drug pricing. Economically, he models a 50/50 split with Merck. He maintains a Buy on Merck with a $166 target, arguing the narrative is shifting from the Keytruda patent cliff to pipeline execution.

Stranahan also outlined hard conditions: the market still does not know how much better the combination is versus Keytruda alone. After discussions with physicians, he believes an RFS hazard ratio around 0.8 would be sufficient to support adoption; a reading of 0.6-0.7 at meetings like ESMO would support a more positive outlook. Forbes cited the same reservation. This explains why a target price upgrade and Thursday's selloff can occur simultaneously - the market is buying "platform validated" while selling "validation lacks a dose."

Commercialization is not automatic. Personalized therapies require rapid sequencing, design, manufacturing, and delivery after surgery, and supply chain and turnaround times will determine real-world penetration. Adjuvant melanoma already has standard immunotherapy, and the incremental benefit must be large enough to change treatment pathways, reimbursement, and hospital workflows. C&EN noted this is the first successful late-stage trial for an mRNA cancer vaccine, but full data have not yet been published, and approval still requires regulatory review.